The considerations mentioned in this piece are a priori. Newly approved drugs must hurdle acceptance by physicians and placement in a formulary tier. No new news here. What if I were to say, "Are crows are birds?" However, some may appreciate this education, but I hope they are not active investors in biotech.
Al Mann knows exactly what needs to be done when the approval letter arrives. When the approval is announced to the public, he will also announce either the partnership or the fact that a bidding process is simultaneously underway. Al Mann is certainly no fool and he will have the last laugh against those who believe that the approval letter marks the beginning of a decline in pps. This company with a prosperous future, and what it does to improve the lives of diabetics around the world, is his legacy.
I agree with your sentiments. There is no law which says the approval must be disseminated to the public at its arrival at Mannkind headquarters. Who knows if it hasn't already arrived? It's up to Mann's discretion.
Sentiment: Strong Buy
Up tomorrow for sure. Great days ahead, however, I'm holding MNKD for many years so I expect hills and valleys until we reach our mountain top vista. GL to all longs.
Bump it up all night long. Pleasant sleep to longs, but for shorts, I offer you my condolences.
It's only a matter of approving a label, not the decision to approve Affreza.
Btw, Todd's article on MF is poorly researched. People who have done DD can see that immediately. He get's paid for eyeballs that see that, so I don't recommend reading him. Waste of time.
Simply ignore their dilettante dribble and concentrate on your DD.
We get an update soon after June completes.
Bashers have a better chance of shaking Vanguard, BlackRock, Fildelity and others out this holding that retail. Let's get real bashers for once and give up your #$%$ backwards posts. You ridicule only yourself. Many people read this MB solely for entertainment, not for investment advice. We're so over you.
Hear's a shout out to Al Mann-a lifetime of business success and topping off his career with a legacy of benefit to the world to revolutionize care for diabetics. Uncountable sufferers have a great chance of reclaiming a decent daily life back, not to mention a leap forward in medical care. I'm so happier for you over the financial gain for myself that awaits.
Management must be discussing this option even if that might not be the action eventually chosen. But I do believe that the market will approve if that's case. Mannkind will have the strongest possible hand in negotiating partnerships...or even a buyout. I will definitely approve if this happens. $500 mil. or more. Easy deal.
At this critical juncture, all options are on the table. Can you imagine the internal dialogue being generated?
Amazing times we are in!
Oh yes, the bong. What there they thinking?
Mannkind hit a home run with the Dreamboat. And also - it's quite important to understand - that Mannkind owns the pharmaceutical space for pulmonary delivery of drugs through encapsulated small molecules. Afrezza is just the beginning to become a worldwide major player.
Al and mgmt are nailing down partnerships with BF; have confidence in that; mb trolls are simply bottom dwellers hoping against hope that inane messages will shake longs. What else can I say?
Anybody care to comment on this question? If Mannkind could develop an inhaling long-acting insulin, Mannkind will be the premier worldwide provider on insulin and delivery devices. (Besides smokers and COPD, of course.) The main companies at the moment will be scrambling to get MDKD locked up.
What say you?
I'm so curious about this. Mannkind solicits partners for alternative drug use by using Techosphere. But why not long-acting insulin? If can be formulated in small molecules, I'm sure it can encapsulated into dry powder. Thanks for your reply. There are no biochemists who can comment? Perhaps an email to to Mannkind might be best way to answer this.
I didn't sell any of my position. It's strange that there was no attempt to address shareholders in any substantial way after approval. Very, very strange. Something's brewing behind closed doors, imo.